medigraphic.com

2010, Number 5

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2010; 48 (5)

Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD-3)

García-Hernández P, Arechavaleta-Granell MR, Yamamoto J, Falahati A, González-Gálvez G

Language: Spanish
References: 22
Page: 543-548
PDF size: 36.91 Kb.


ABSTRACT

Objective: to compare the efficacy of liraglutide monotherapy with glimepiride monotherapy in subjects with DM2 inadequately controlled by previous treatment of diet/exercise or oral antidiabetic drug.
Methods:a 52-week, double-blinded, active-controlled, parallel-group, multi-centre, prospective trial, involving 746 subjects was conducted in the USA and Mexico. In Mexico, 171 subjects were randomised (1:1:1) to once daily liraglutide (either 1.2, or 1.8 mg/day injected subcutaneously) or glimepiride (8 mg/day orally).
Results: Hb1Ac reduced by 0.64 %, 1.31 % and 0.30 % with glimepiride, liraglutide 1.8 mg and 1.2 mg, respectively. Body weight decreased with both liraglutide doses while a weight gain of 0.94 kg was observed with glimepiride. FPG reduced by 27.9 mg/dL with liraglutide 1.8 mg, whereas a FPG increase of 9.54 mg/dL was shown with glimepiride. No major hypoglycaemic episodes were reported in this trial.
Conclusions: in Mexican subjects with DM2, liraglutide monotherapy can provide greater reduction in HbA1c, weight loss and lower risk of hypoglycaemia in comparison with glimepiride.


REFERENCES

  1. UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258.

  2. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-1972.

  3. Green J, Feinglos M. Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. Int J Clin Pract 2007;61:3-11.

  4. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.

  5. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

  6. Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 2005;27 (Suppl B):1-18.

  7. Rolfing CL, Wiedmeyer HS, Little RR, England JD, Tennill A, Goldstein DE, et al. Defining the relationship between plasma glucose and HbA1c. Diabetes Care 2002;25:275-278.

  8. Holst JJ. Enteroglucagon. Annu Rev Physiol 1997; 59:257-271.

  9. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2(8571):1300-1304.

  10. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckle D, Schmidt WE, Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004;53:654-662.

  11. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439.

  12. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000;43:1664-1669.

  13. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202.

  14. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of GLP-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998;41:271-278.

  15. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male patients. Diabetes Care 2002;25:1398-1404.

  16. Drucker DJ, Nauck MA. The incretin system: glucagon- like peptide- 1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet 2006;368:1696-1705.

  17. Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med 2009;121(3):5-15.

  18. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assemble, Washington 2002, and Note of Clarification on Paragraph 30 by the WMA General Assembly, Tokyo 2004. Disponible en http//:www.wma.net/e/policy/b3.htm

  19. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline, Good Clinical Practice, 1996. Disponible en http://www.ich.org/ LOB/media/MEDIA482.pdf

  20. Garber A, Henry R, Ratner R; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662): 473-481.

  21. Davies M. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord 2004;28(Suppl 2): S14-S22.

  22. Drucker DJ, Nauck MA. The incretin system: glucagon- like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368(9548):1696-1705.




2020     |     www.medigraphic.com